Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

No serious adverse events were reported. Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the cream regained 75% or more skin re ...

In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the cream regained 75% or more skin re ...

Wayde Cadogan bares all on TikTok as she turns her alopecia diagnosis into a platform for awareness, self-acceptance and a redefining of beauty standards Ashley Vega is a writer-reporter at PEOPLE.

On Monday, the soda giant announced that it's releasing Coca-Cola Orange Cream. According to the brand, the new drink is a "delicious taste of Coca-Cola infused with refreshing orange and smooth ...

Celiac disease is associated with an increased risk for developing alopecia areata, according to a letter to the editor published online in the Journal of the American Academy of Dermatology. Rashwan ...